Advances in early detection and treatment have significantly improved survival outcomes, especially in non-metastatic cases. However, prognosis varies greatly depending on the stage at diagnosis, molecular characteristics, and the extent of metastasis.

Fund managers should begin by asking their underwriters whether and how wealth is factored into the life expectancy estimates.

Life Risk News Q&A: Matthew Sheridan of Health Data Analytics Institute to get his thoughts on how predictive modelling is helping US health systems to better triage patients and model risk.

The Irish pension risk transfer market slow to get going amidst regulatory logjams.